scholarly journals P.113 A Population-based Study of the Epidemiology, Healthcare Resource Utilization and Costs of Duchenne Muscular Dystrophy in Alberta, Canada

2021 ◽  
Vol 48 (s3) ◽  
pp. S51-S51
Author(s):  
G Chen ◽  
B Sharif ◽  
MS Farris ◽  
T Cowling ◽  
C Cabalteja ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Resource Utilization ◽  
Healthcare Resource ◽  
Treatment Strategies ◽  
Medical Costs ◽  
Population Based ◽  
Healthcare Resource Utilization ◽  
First Year ◽  
Diagnostic Code

Background: Duchenne muscular dystrophy (DMD) is a severe progressive neuromuscular disease. This study aimed to estimate the prevalence, healthcare resource utilization (HRU), and medical costs of DMD in Alberta. Methods: This retrospective study linked provincial healthcare administrative data to identify patients with DMD utilizing a modified diagnostic code algorithm, including males <30 years of age. Five-year (April 2012 to March 2017) prevalence estimates were calculated and all-cause direct HRU and costs were examined in the first-year post-diagnosis. Results: Overall, 111 patients (median age: 12.0 years (IQR 4.7-18.3)) with DMD were identified. The estimated five-year period prevalence was 35.72 (95% CI 31.88-39.91) per 100,000 persons. All-cause HRU in the first-year post-diagnosis included a mean (SD) of 0.48 (1.19) hospitalizations (length of stay: 9.37 days (36.47)), 3.96 (6.16) general practitioner visits, 28.52 (62.98) specialist visits, and 20.14 (16.49) ambulatory care visits. Mean (SD) all-cause direct costs were $18,868 ($29,206) CAD in the first-year post-diagnosis. Conclusions: Patients with DMD had multiple interactions with the healthcare system in the year following diagnosis, resulting in substantial direct medical costs. More effective treatment strategies are needed to improve health outcomes and reduce the burden of DMD.

Abstract 240: Cardiovascular-related Healthcare Resource Utilization and Costs among Patients with Hypertension Switching From Metoprolol to Nebivolol

2014 ◽  
Vol 7 (suppl_1) ◽  
Author(s):  
Stephanie Chen ◽  
An-Chen Fu ◽  
Rahul Jain ◽  
Hiangkiat Tan
Keyword(s):  
Resource Utilization ◽  
Healthcare Resource ◽  
Beta Blockers ◽  
Medical Costs ◽  
Healthcare Resource Utilization ◽  
Study Cohort ◽  
Research Database ◽  
Branded Drug ◽  
Pharmacy Claims ◽  
Post Period

Background: Metoprolol is a commonly prescribed β-blocker for hypertension in the US. Evidence suggests that the vasodilating β1-blocker, nebivolol, is superior to non-vasodilating beta-blockers, such as metoprolol, in lowering central blood pressure, an effect which is thought to be highly correlated to future cardiovascular (CV) risk. The aim of this study was to evaluate CV-related healthcare resource utilization (HCRU) and costs before and after patients switched from metoprolol to nebivolol for hypertension treatment. Methods: This retrospective study utilized medical and pharmacy claims from HealthCore-Integrated-Research-Database with 14 US commercial health plans representing over 33 million lives. The study cohort included only patients who were initially taking metoprolol for at least 6 months (pre-period) and then switched to nebivolol and remained on it for at least 6 months (post-period). The date of switching to nebivolol between 1/1/ 2008 and 12/31/2012 was defined as the index date. Patients were excluded if they had angina, myocardial infarction and congestive heart failure (compelling indications for metoprolol but not for nebivolol); unstable regimen of background antihypertensive medication at the drug class level; or did not have continuous health plan enrollment during these two periods. CV-related HCRU (per-100 patient-per-month) and costs (per-patient-per-month (PPPM)) were calculated for pre- and post- periods respectively by type of service - hospitalizations (INP), emergency room (ER) visits, and outpatient (OP) visits. Bootstrapping t-test was used to compare the differences of HCRU and costs between these two periods. Results: There were 765 patients included in the study with mean age 55(±11)years, 59% males and mean Deyo-Charlson Comorbidity Index (DCI) score of 0.5(±0.9). Relative to pre-period, the number of CV-related ER visits and CV-related OP visits per-100 patient-per-month were significantly lower in the post-period (ER: 0.17±1.88 vs.0.04±0.84, p=0.012; OP: 9.2±19.9 vs. 6.7±17.5, p<0.001). No differences were observed in number of CV-related INP visits. Additionally, relative to the pre-period, the ER cost and the total CV-related medical were significantly lower in the post-period (ER: $6 ±$78 vs. $1±$27 PPPM, p=0.028; total CV-related medical costs: $94±$526 vs. $54±$266 PPPM, p=0.020). There were no differences found in INP or OP costs. Conclusions: This study suggests that hypertensive patients switching from metoprolol to nebivolol have lower CV-related ER and OP visits as well as lower total CV-related medical costs, despite higher pharmacy costs after switching from a generic to a branded drug. Further studies are needed to identify these key drivers.

scholarly journals First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan

2021 ◽  
Vol 18 (18) ◽  
pp. 9447
Author(s):  
Tomone Watanabe ◽  
Rei Goto ◽  
Yoko Yamamoto ◽  
Yuichi Ichinose ◽  
Takahiro Higashi
Keyword(s):  
Health Service ◽  
Service Utilization ◽  
Resource Utilization ◽  
Cancer Registry ◽  
Health Service Utilization ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
First Year ◽  
Cancer Type ◽  
Utilization Data

Reports on the expenditure of cancer treatments per patient using comprehensive data remain unavailable in Japan. This study aimed to use Japan’s cancer registry data and health service utilization data for evaluating the disease-specific, per-patient costs of five major cancers—stomach, lung, colorectal, liver, and breast cancers. We used a database linking the 2017 data from a hospital-based cancer registry and the health service utilization data from the Diagnosis Procedure Combination survey. All patients who started their first treatment course at each hospital were included. The costs were calculated using the total volume of the health services provided and the unit fee information included in the data. We analyzed 304,698 patients. Lung cancer had the highest healthcare cost per-patient for the first year of diagnosis and the longest median hospitalization duration. Conversely, breast cancer showed the lowest cost and the shortest median hospitalization duration. However, in the first month after diagnosis, colorectal cancer showed the highest cost. Subsequently, the gaps between the costs of the five common cancers drastically diminished. The cancer type having the longest hospitalization duration had the highest overall healthcare resource utilization costs. This information is essential for care planning and research studies.

Treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs).

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 337-337 ◽  
Author(s):  
Beilei Cai ◽  
Michael Broder ◽  
Eunice Chang ◽  
Jessie Tingjian Yan ◽  
Al Bowen Benson
Keyword(s):  
Treatment Adherence ◽  
Resource Utilization ◽  
Index Date ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
First Year ◽  
Office Visits ◽  
Second Year ◽  
Pharmacologic Treatments

337 Background: This study aimed to assess treatment adherence, healthcare resource utilization and costs in patients with GI NETs who initiated pharmacologic treatments. Methods: In 2 US commercial claims databases, patients ≥18 years with ≥1 inpatient or ≥2 outpatient claims for GI NETs were identified. The first claim for pharmacologic treatments (e.g. somatostatin analogues [SSAs], cytotoxic chemotherapy [CC], targeted therapy) following diagnosis and between 7/1/2009 and 12/31/2013 was defined as the index date. A 6-month clean period before index date and a 6-month pre- and a ≥1-year post-index enrollment were required. Proportion of days covered (PDC) was calculated during the follow up period. Outcomes were reported separately for patients with 1 and 2 years of post-index enrollment. Descriptive statistics including means, standard deviations, and frequencies and percentages for continuous and categorical data, respectively, were reported. Results: Of 1,322 patients with 1-year of follow-up, 847 initiated SSAs, 397 CC, 35 targeted therapies, 2 interferon, and 41 various combinations. Due to sample sizes, remaining results focus only on SSAs and CC. Mean PDC (SD) was 0.669 (0.331) for SSAs and 0.466 (0.236) for CC; SSA users had 20.5 (13.5) office visits and 0.59 (1.03) hospitalizations, CC users had 30.5 (19.8) and 0.89 (1.45) office visits and hospitalizations respectively; total annual cost for SSA-treated patients during the 1st year was $99,691 (82,423) and $134,912 (116,078) for CC. Among 685 patients with 2 years of follow-up, the annual mean costs in the second year were $8,071 and $58,944 lower than the first year for SSAs and CC, respectively. Conclusions: In this descriptive non-comparative study, we reported the resource utilization and costs associated with different treatment therapies. Overall, costs were higher in the first year than in the second year. This 2-database study offers new information on the magnitude and trends in the cost of pharmacologically treated GI NETs. Additional research with a larger sample size would be needed to better understand real-world utilization and costs for GI NET patients treated with different pharmacological therapies.

Sign in / Sign up

Export Citation Format

Share Document